Lawmakers believe their breakthrough bill will lower drug costs. It may not.

The industry that negotiates drug prices for employers has worked to stay ahead of the game.

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual ...

Scienture Holdings, Inc.: SCIENTURE Provides Commercial Update on ARBLI, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Company highlights accelerating access and revenue growth for ARBLI and confirms REZENOPY launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Ou ...
Managed Healthcare Executive

PBM reform. It has finally happened

The funding legislation the House passed today that President Trump is expected to sign into law includes expansive changes to how pharmacy benefit managers (PBMs) are regulated that could usher in a ...
The American Journal of Managed Care

PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency

PBMs typically receive a portion of rebates paid by drug manufacturers, the majority of which are passed back to the payer as an incentive to prefer a drug on a formulary. PBMs may also retain revenue ...
PlasticsToday

Assessing the US Packaging Market: Trends and Regulations

US packaging market grows to $319B by 2035 driven by sustainability rules, ecommerce boom, and regulatory policy changes ...